Kinetics, thermodynamics, and mechanisms of PMO interactions from computational molecular modeling.

Ying Chou, Igor Novikov, Daniel Pierson, Kenneth A Marx, Arani Chanda, Valeri Barsegov

Abstract read

In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ying ChouDepartment of Chemistry, University of Massachusetts, Lowell, MA 01854, USA.

Igor NovikovDepartment of Chemistry, University of Massachusetts, Lowell, MA 01854, USA.

Daniel PiersonSarepta Therapeutics, Cambridge, MA 02142, USA.

Kenneth A MarxDepartment of Chemistry, University of Massachusetts, Lowell, MA 01854, USA.

Arani ChandaSarepta Therapeutics, Cambridge, MA 02142, USA.

Valeri BarsegovDepartment of Chemistry, University of Massachusetts, Lowell, MA 01854, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phosphorodiamidate morpholino oligonucleotides (PMOs) are a class of antisense oligonucleotides. While PMOs have enabled several nucleic acid therapeutics, their structural and energetic solution properties remain poorly understood. Using solution viscosity measurements combined with computational molecular modeling, we explored interactions of therapeutic 22-mer, 25-mer, and 30-mer PMOs in concentrated solutions. Self-association of PMO monomers involves non-specific interactions, is energetically favorable (with estimates of -32 to -67 kcal/mol interaction energies), and exhibits biphasic kinetics involving a fast phase of hydrophobic anchoring followed by a slower phase associated with optimization of intermolecular base pairing and stacking interactions. The final complexes possess broad self-association interfaces of ∼700-1,600 Å

Indexed as

antisense oligonucleotidesbiomolecular interactionscomputational molecular modelingDuchenne muscular dystrophyformulationmolecular dynamics simulationsMT: oligonucleotides: therapies and applicationsphosphorodiamidate morpholino oligomersviscosity

Identifiers

PMID42668701

DOI10.1016/j.omtn.2026.103056

PMCPMC13524873

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.